The Efficacy of Lambrolizumab in Advanced Melanoma

June 17, 2013
Antoni Ribas, MD, PhD

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Clinical Pearls

Researchers have seen clinically meaningful activity in a substantial number of patients, Ribas says. In the trial, the overall response rate was 38% and 90% of patients experienced durable response. Ribas notes that adverse events in the trial were minimal.

  • Clinically meaningful activity was observed in the trial
  • The overall response rate was 38%, pooled across all doses and schedules and including both ipilimumab-naive and ipilimumab-pretreated patients
  • Preliminary data suggest that lambrolizumab has significant antitumor activity and is well tolerated with manageable side effects in both ipilimumab-naive and ipilimumab-pretreated patients with melanoma

<<<

View all coverage from the 2013 ASCO Meeting